Stolen Drugs Highlighted in August and September Recalls
This article was originally published in The Gold Sheet
Drug diversion risks highlighted in August, September recalls.
You may also be interested in...
Rash of pharmaceutical cargo and warehouse thefts lead to responses by FDA, industry
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.